| Travoprost |
20140185 |
Bondulc, Eye drops, solution, 40 mcg/ml - 2.5ml, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
PHARMATHEN S.A., Гърция; Балканфарма - Разград АД, България |
9.25 |
1.85 |
11.1 |
7% |
0.65 |
9.9 |
1.98 |
11.88 |
20% |
1.85 |
11.75 |
2.35 |
14.1 |
|
НСР-7808/28.12.2015 |
13.01.2016 |
13.01.2016 |
Неактивен |
3315 |
| Travoprost |
20140185 |
Bondulc, Eye drops, solution, 40 mcg/ml - 2.5ml, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
PHARMATHEN S.A., Гърция; Балканфарма - Разград АД, България |
9.25 |
1.85 |
11.1 |
7% |
0.65 |
9.9 |
1.98 |
11.88 |
20% |
1.85 |
11.75 |
2.35 |
14.1 |
|
НСР-7808/28.12.2015 |
13.01.2016 |
13.01.2016 |
Неактивен |
3315 |
| Travoprost |
20140185 |
Bondulc, Eye drops, solution, 40 mcg/ml - 2.5ml, mg, Pack: 1 |
Actavis Group PTC ehf., Исландия |
PHARMATHEN S.A., Гърция; Балканфарма - Разград АД, България |
15.29 |
3.06 |
18.35 |
6% |
0.92 |
16.21 |
3.24 |
19.45 |
18% |
2.75 |
18.96 |
3.79 |
22.75 |
|
НСР-4969/29.10.2014 |
12.11.2014 |
12.11.2014 |
Неактивен |
3315 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 1 mg/ml - 3 ml, -, Pack: 1 pre-filled syringe (glass) |
Atnahs Pharma UK Limited, Обединено Кралство |
Roche Pharma AG - Germany |
49.31 |
9.86 |
59.17 |
4% |
1.97 |
51.28 |
10.26 |
61.54 |
16% |
7.89 |
59.17 |
11.83 |
71 |
Промяна на обстоятелствата НСР-16766/07.09.2018 |
НСР-7186/09.10.2015; НСР-10933/17.11.2016; НСР-18004/21.02.2019 |
08.03.2019 |
02.04.2019 |
Активен |
3110 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 1 mg/ml - 3 ml, -, Pack: 1 pre-filled syringe (glass) |
Atnahs Pharma UK Limited, Обединено Кралство |
Roche Pharma AG - Germany |
50.32 |
10.06 |
60.38 |
4% |
2.01 |
52.33 |
10.47 |
62.8 |
16% |
8.05 |
60.38 |
12.08 |
72.46 |
Промяна на обстоятелствата НСР-16766/07.09.2018 |
НСР-7186/09.10.2015; НСР-10933/17.11.2016 |
06.12.2016 |
02.10.2018 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 1 mg/ml - 3 ml, -, Pack: 1 pre-filled syringe (glass) |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
50.32 |
10.06 |
60.38 |
4% |
2.01 |
52.33 |
10.47 |
62.8 |
16% |
8.05 |
60.38 |
12.08 |
72.46 |
|
НСР-7186/09.10.2015; НСР-10933/17.11.2016 |
06.12.2016 |
02.01.2017 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 1 mg/ml - 3 ml, -, Pack: 1 pre-filled syringe (glass) |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
50.38 |
10.08 |
60.46 |
4% |
2.02 |
52.4 |
10.48 |
62.88 |
16% |
8.06 |
60.46 |
12.09 |
72.55 |
|
НСР-7186/09.10.2015 |
24.10.2015 |
24.10.2015 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/003 |
Bonviva, Film coated tablet, 150, mg, Pack: 1 |
Atnahs Pharma UK Limited, Обединено Кралство |
Roche Pharma AG - Germany |
16.29 |
3.26 |
19.55 |
6% |
0.98 |
17.27 |
3.45 |
20.72 |
18% |
2.93 |
20.2 |
4.04 |
24.24 |
Промяна на обстоятелствата НСР-16767/07.09.2018 |
НСР-6543/24.06.2015 |
10.07.2015 |
02.10.2018 |
Активен |
2738 |
| Ibandronic acid |
EU/1/03/265/003 |
Bonviva, Film coated tablet, 150, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
16.29 |
3.26 |
19.55 |
6% |
0.98 |
17.27 |
3.45 |
20.72 |
18% |
2.93 |
20.2 |
4.04 |
24.24 |
|
НСР-6543/24.06.2015 |
10.07.2015 |
10.07.2015 |
Неактивен |
2738 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 3 mg/3 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
52.83 |
10.57 |
63.4 |
4% |
2.11 |
54.94 |
10.99 |
65.93 |
16% |
8.45 |
63.39 |
12.68 |
76.07 |
|
НСР-4320/05.08.2014 |
20.08.2014 |
20.08.2014 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/003 |
Bonviva, Film coated tablet, 150, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
19.71 |
3.94 |
23.65 |
6% |
1.18 |
20.89 |
4.18 |
25.07 |
18% |
3.55 |
24.44 |
4.89 |
29.33 |
|
НСР-3306/24.04.2014 |
08.05.2014 |
08.05.2014 |
Неактивен |
2738 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 3 mg/3 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
88.72 |
17.74 |
106.46 |
4% |
3.55 |
92.27 |
18.45 |
110.72 |
16% |
14.2 |
106.47 |
21.29 |
127.76 |
|
НСР-1917/27.11.2013 |
19.12.2013 |
19.12.2013 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 3 mg/3 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
141.37 |
28.27 |
169.64 |
4% |
5.65 |
147.02 |
29.4 |
176.42 |
16% |
22.62 |
169.64 |
33.93 |
203.57 |
|
КЦРР-1304/21.08.2012 |
11.09.2012 |
11.09.2012 |
Неактивен |
3110 |
| Ibandronic acid |
EU/1/03/265/003 |
Bonviva, Film coated tablet, 150, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
43.42 |
8.68 |
52.1 |
4% |
1.74 |
45.16 |
9.03 |
54.19 |
16% |
6.95 |
52.11 |
10.42 |
62.53 |
|
КЦ-529/13.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
2738 |
| Ibandronic acid |
EU/1/03/265/005 |
Bonviva, Solution for injection, 3 mg/3 ml, mg, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
148.64 |
29.73 |
178.37 |
4% |
5.95 |
154.59 |
30.92 |
185.51 |
16% |
23.78 |
178.37 |
35.67 |
214.04 |
КЦ-1221/18.12.2009 промяна на обстоятелства |
КЦ-529/13.02.2009 |
02.03.2009 |
02.03.2009 |
Неактивен |
3110 |
| pertussis, purified antigen, combinations with toxoids |
II-16189 / 05.04.2007 г. |
Boostrix, Suspension for injection, 1 dose(0,5 ml), -, Pack: 1 pre-filled syringe 0.5 ml + 2 needles |
ГлаксоСмитКлайн ЕООД, България |
GlaxoSmithKline Biologicals S.A., rue de l’Institut 89, 1330 Rixensart, Belgium |
21.83 |
4.37 |
26.2 |
6% |
1.31 |
23.14 |
4.63 |
27.77 |
18% |
3.93 |
27.07 |
5.41 |
32.48 |
|
КЦ-262/27.10.2008 |
18.11.2008 |
18.11.2008 |
Активен |
127 |
| diphtheria-pertussis-poliomyelitis-tetanus |
20120314 |
Boostrix polio, Suspension for injection, 1 dose(0,5 ml), -, Pack: 1 pre-filled syringe + 1 needle |
ГлаксоСмитКлайн ЕООД, България |
Glaxo Smith Kline BOILOGICALS sa, Belgium |
33.7 |
6.74 |
40.44 |
4% |
1.35 |
35.05 |
7.01 |
42.06 |
16% |
5.39 |
40.44 |
8.09 |
48.53 |
|
НСР-5459/16.01.2015 |
02.02.2015 |
02.02.2015 |
Активен |
3515 |
| diphtheria-pertussis-poliomyelitis-tetanus |
20120314 |
Boostrix polio, Suspension for injection, 1 dose(0,5 ml), -, Pack: 1 pre-filled syringe + 1 needle |
ГлаксоСмитКлайн ЕООД, България |
Glaxo Smith Kline BOILOGICALS sa, Belgium |
33.7 |
6.74 |
40.44 |
4% |
1.35 |
35.05 |
7.01 |
42.06 |
16% |
5.39 |
40.44 |
8.09 |
48.53 |
|
НСР-5459/16.01.2015 |
02.02.2015 |
02.02.2015 |
Неактивен |
3515 |
| diphtheria-pertussis-poliomyelitis-tetanus |
20120314 |
Boostrix polio, Suspension for injection, 2 IU/20 IU/8µ/8µ/2,5µ, IU, Pack: 1 dose (0,5 ml) |
ГлаксоСмитКлайн ЕООД, България |
Glaxo Smith Kline BOILOGICALS sa, Belgium |
34.81 |
6.96 |
41.77 |
4% |
1.39 |
36.2 |
7.24 |
43.44 |
16% |
5.57 |
41.77 |
8.35 |
50.12 |
|
НСР-2753/17.02.2014 |
03.03.2014 |
03.03.2014 |
Неактивен |
3515 |
| diphtheria-pertussis-poliomyelitis-tetanus |
20120314 |
Boostrix polio, Suspension for injection, 2 IU/20 IU/8µ/8µ/2,5µ, IU, Pack: 1 dose (0,5 ml) |
ГлаксоСмитКлайн ЕООД, България |
Glaxo Smith Kline BOILOGICALS sa, Belgium |
35.24 |
7.05 |
42.29 |
4% |
1.41 |
36.65 |
7.33 |
43.98 |
16% |
5.64 |
42.29 |
8.46 |
50.75 |
|
КЦРР-1673/20.11.2012 |
06.12.2012 |
06.12.2012 |
Неактивен |
3515 |
| Bortezomib |
20150346 |
Bortega, Powder for solution for injection, 3.5, mg, Pack: 1 |
Heaton k.s., Чешка република |
Heaton k.s., Чешка република |
1125.35 |
225.07 |
1350.42 |
4% |
10 |
1135.35 |
227.07 |
1362.42 |
16% |
25 |
1160.35 |
232.07 |
1392.42 |
|
НСР-14543/30.11.2017 |
15.12.2017 |
02.01.2018 |
Активен |
4186 |
| Bortezomib |
20150346 |
Bortega, Powder for solution for injection, 3.5, mg, Pack: 1 |
Heaton k.s., Чешка република |
PharmIdea SIA, Латвия |
1131.25 |
226.25 |
1357.5 |
4% |
10 |
1141.25 |
228.25 |
1369.5 |
16% |
25 |
1166.25 |
233.25 |
1399.5 |
|
НСР-8087/12.02.2016.; НСР-12709/12.05.2017 |
27.02.2016 |
02.06.2017 |
Заличен |
4186 |
| Bortezomib |
20150346 |
Bortega, Powder for solution for injection, 3.5, mg, Pack: 1 |
Heaton k.s., Чешка република |
PharmIdea SIA, Латвия |
1131.25 |
226.25 |
1357.5 |
4% |
10 |
1141.25 |
228.25 |
1369.5 |
16% |
25 |
1166.25 |
233.25 |
1399.5 |
|
НСР-8087/12.02.2016. |
27.02.2016 |
27.02.2016 |
Неактивен |
4186 |
| Bortezomib |
20150346 |
Bortega, Powder for solution for injection, 3.5, mg, Pack: 1 |
Дуче Фарм ЕООД, България |
PharmIdea SIA, Латвия |
1131.25 |
226.25 |
1357.5 |
4% |
10 |
1141.25 |
228.25 |
1369.5 |
16% |
25 |
1166.25 |
233.25 |
1399.5 |
|
НСР-8087/12.02.2016. |
27.02.2016 |
27.02.2016 |
Неактивен |
4186 |
| Bortezomib |
20170302 |
Bortezocon, Powder for solution for injection, 3.5, mg, Pack: 1 |
Фармаконс АД, България |
Фармаконс АД, България |
1125.58 |
225.12 |
1350.7 |
4% |
10 |
1135.58 |
227.12 |
1362.7 |
16% |
25 |
1160.58 |
232.12 |
1392.7 |
|
НСР-14714/20.12.2017 |
06.01.2018 |
02.02.2018 |
Активен |
15990 |